Haploid human ESCs:
The Clear 23

By eliminating drugs that are ineffective for a specific patient, NewStem can increase treatment efficacy and the patient’s survival.

In nearly 50% of all cancer cases, resistance to anti-cancer drugs exists in the tumors before the initiation of the drug treatment (innate resistance). Treating patients with ineffective anti-cancer drugs results in major health hazards, unnecessary suffering and is expensive. It, therefore, would be of great value for patients, their physicians, and medical insurers, to identify resistance to the drug prior to commencing treatment with antineoplastic substances.

0%
Anti-Cancer Drugs Resistance Rate
0
Cancer Deaths a Year Worldwide
0
New Cancer Cases a Year Worldwide

NewStem Diagnostic is an expansive, sustainable and personalized rapid screening for anti-cancer drugs resistance based on the specific characterization of the patient’s cancer mutagenicity. The product is expected to reach the market within two years.

The Process

Step 1

Discovered Haploid human Embryonic Stem Cells (HhESCs)

Step 2

Generated a comprehensive library of mutated HhESC genes

Step 3

Performing powerful genetic screenings for gene confer resistance to anti-cancer drugs

Step 4

Establishing an extensive database

Step 5

Integration of NewStem’s database with the patient’s cancer mutagenicity profile

Step 6

Recommendations are sent to the doctor

NewStem’s technology can predict patients’ resistance to anti-cancer drugs, allowing for better, targeted cancer treatments.